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for the classification of ovarian masses
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Chada Baracat, Jesus Paula Carvalho
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OBJECTIVE: Differentiation between benign and malignant ovarian neoplasms is essential for creating a system for
patient referrals. Therefore, the contributions of the tumor markers CA125 and human epididymis protein 4 (HE4) as
well as the risk ovarian malignancy algorithm (ROMA) and risk malignancy index (RMI) values were considered
individually and in combination to evaluate their utility for establishing this type of patient referral system.
METHODS: Patients who had been diagnosed with ovarian masses through imaging analyses (n = 128) were assessed
for their expression of the tumor markers CA125 and HE4. The ROMA and RMI values were also determined. The
sensitivity and specificity of each parameter were calculated using receiver operating characteristic curves according
to the area under the curve (AUC) for each method.
RESULTS: The sensitivities associated with the ability of CA125, HE4, ROMA, or RMI to distinguish between
malignant versus benign ovarian masses were 70.4%, 79.6%, 74.1%, and 63%, respectively. Among carcinomas, the
sensitivities of CA125, HE4, ROMA (pre- and post-menopausal), and RMI were 93.5%, 87.1%, 80%, 95.2%, and
87.1%, respectively. The most accurate numerical values were obtained with RMI, although the four parameters
were shown to be statistically equivalent.
CONCLUSION: There were no differences in accuracy between CA125, HE4, ROMA, and RMI for differentiating
between types of ovarian masses. RMI had the lowest sensitivity but was the most numerically accurate method. HE4
demonstrated the best overall sensitivity for the evaluation of malignant ovarian tumors and the differential
diagnosis of endometriosis. All of the parameters demonstrated increased sensitivity when tumors with low
malignancy potential were considered low-risk, which may be used as an acceptable assessment method for
referring patients to reference centers.
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INTRODUCTION
Ovarian cancer is the seventh most common cancer in
women and is not diagnosed before reaching an advanced
stage in approximately 70% of all cases. As a consequence,
the 5-year survival rate associated with ovarian cancer is
less than 30% (1,2). Therefore, both surgical staging and the
performance of optimal cytoreduction procedures in refer-
ence centers may have a substantial impact on patient
survival.
Over 90% of all ovarian masses detected in pre-meno-
pausal women and up to 60% of masses found in post-
menopausal women are benign (3). Thus, it is crucial to
assess risk for women who present with pelvic masses, as
this process should optimize health policies without over-
burdening reference centers. Currently, the tumor markers
CA125 and human epididymis protein 4 (HE4) as well as
the risk ovarian malignancy algorithm (ROMA) and risk
malignancy index (RMI) values are used as tools for
differentiating between low- and high-risk patients with
ovarian cancer. In more than 85% of advanced-stage ovarian
carcinoma cases, the levels of CA125 have been found to be
elevated above the cutoff value for high-risk patients
(.35 U/ml). In contrast, the levels of CA125 are elevated
in only 50% of early-stage ovarian carcinoma cases (4).
Moreover, in post-menopausal women, CA125 values
greater than 95 U/ml are associated with a positive
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predictive value of 95% (5). HE4 is a recently discovered
tumor marker that has been shown to have a sensitivity of
72.9% and a specificity of 95% for differentiating between
types of ovarian masses, and these values are higher than
those related to the use of CA125 (6). In 2009, Moore et al. (7)
proposed that the ROMA value, which takes into account
the levels of CA125 and HE4 together with menopausal
status, could be used to evaluate ovarian masses using only
quantitative and objective parameters. The use of this
algorithm in cohorts of pre- and post-menopausal women
resulted in a sensitivity of 88.7% and a specificity of 74.7%
(7). Almost 20 years prior to the development of the ROMA,
Jacobs et al. (8) created the RMI, which takes into account
the CA125 value, menopausal status, and ultrasound
parameters. RMI values greater than 200 were shown to
be associated with a higher risk of malignancy and
demonstrated a sensitivity of 85.4% and a specificity of
96.9% (8).
In this study, we aimed to compare these four methods,
namely the CA125 and HE4 measurements and the ROMA
and RMI values, in regards to their ability to differentiate
low- versus high-risk pelvic masses initially suspected to be
of ovarian origin.
PATIENTS AND METHODS
This was a prospective study conducted at the
Department of Obstetrics and Gynecology of the
Universidade de Sa˜o Paulo and the Instituto do Caˆncer do
Estado de Sa˜o Paulo (Sa˜o Paulo, Brazil) between June 2008
and January 2011. The study was approved by the Ethical
Committee for Research Projects of the Hospital das Clı´nicas
da Faculdade de Medicina da Universidade de Sa˜o Paulo
(CAPPesq) (protocol 1067/08), and all of the patients
provided informed consent.
Study population
A total of 128 patients between the ages of 15 and 90 years
were referred to our hospital with pelvic masses, which
were thought to be of ovarian origin as diagnosed by
ultrasonography, computed tomography (CT), or magnetic
resonance (MR). The women included in the study under-
went surgery or imaging-guided biopsy when they pre-
sented signs of carcinomatosis. The levels of CA125 and
HE4 were measured, and the ROMA and RMI scores were
calculated as previously described (7,8). The pre-menopau-
sal patients were evaluated outside of the menstrual period.
We considered post-menopausal patients to be those over 50
years of age or those over 40 years of age who had not
experienced menses for at least one year. The exclusion
criteria included pregnancy, peritoneal dialysis, any pre-
viously diagnosed disease commonly associated with an
increase in CA 125 (such as mesothelioma), and non-ovarian
tumors.
CA125 and HE4 assays
On the day of surgery or imaging-guided biopsy, two
blood samples (3-5 ml each) were collected before the
procedure. One sample was analyzed for the CA125 level
using a CobasH 4000 analyzer series and the 411 module for
immunoassays (RocheH, USA). The second sample was
centrifuged and stored at -80 C˚, and the level of HE4 was
subsequently determined using an HE4 enzyme immunoas-
say (EIA) (Fujirebio Diagnostics Inc., Goteborg, Sweden).
ROMA calculations
The ROMA was calculated as described by Moore et al.
(7). The predictive index values were calculated as follows:
pre-menopausal Predictive Index (PI) =212.0+2.38*LN
(HE4)+0.0626*LN(CA125); and post-menopausal PI =28.09
+1.04*LN(HE4)+0.732*LN(CA125). In addition, the Predi-
cted Probability (PP) was calculated as: PP = exp(PI)/
[1+exp(PI)].
RMI Calculations
The RMI was calculated according to the criteria
described by Jacobs et al. (8) as follows:
RMI = UxMxserum CA125,
where U = 0 for an ultrasound score of 0, U = 1 for an
ultrasound score of 1, and U = 3 for an ultrasound score of 2-
5 and M = 1 for pre-menopausal women and M = 3 for post-
menopausal women. If the patient underwent CT or MR
prior to ultrasound, the parameters for the sonographic
evaluations were identical to those described by Jacobs et al.
(8) and Moore et al. (9). Although the RMI parameters had
been validated with ultrasound parameters, we used the
same ultrasound parameters for CT and RM as those used
by Moore et al. (9).
Cutoff values
The cutoff values for CA125 and HE4 were 35 U/ml (as
recommended by the manufacturer) and 70 pM [as used by
Moore, et al. (9)], respectively. These cutoff values were the
same as those used for the validation of the ROMA (7). The
ROMA cutoff values for high-risk patients were$13.1% and
$27.7% for pre-menopausal and post-menopausal women,
respectively, as suggested by Moore et al. (7). The cutoff
RMI value for differentiating between benign versus
malignant masses was 200, as proposed by Jacobs et al. (8)
We determined the optimal cutoff value for the CA125 and
HE4 tumor markers as well as the ROMA and RMI by
analyzing the point of greatest accuracy in the receiver
operating characteristic (ROC) curves.
Data Analysis
The sensitivity and specificity for CA125, HE4, ROMA,
and RMI were calculated. The ROC curves and area under
the curve (AUC) values were calculated to compare the
accuracy of each method for predicting malignant ovarian
masses. The statistical analyses were performed using
MedCalc v11.1.1.0 (MedCalc Software, Mariakerke,
Belgium) (10). For all of the statistical comparisons, a level
of p,0.05 was accepted as statistically significant.
RESULTS
Eight patients were excluded from this study for the
following reasons: technical problems were encountered
with the samples from five patients, one patient had a
subserosal leiomyoma instead of an ovarian mass, one
patient was being treated with peritoneal dialysis, and one
patient had been diagnosed with mesothelioma.
The characteristics of the studied population, including
age, menopausal status, and the mean and median levels of
CA125 and HE4 as well as the RMI and ROMA values, are
shown in Table 1. The tumors in this cohort were classified
into two groups consisting of those with a low- or high-risk
for ovarian malignancy. The low-risk tumors included
teratomas (n = 16), endometriomas (n = 13), fibromas
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(n = 4), mucinous cystadenomas (n = 11), serous cystadeno-
mas (n = 14), Brenner tumors (n = 2), and simple cysts (n = 6).
The high-risk tumors included low-malignant-potential
(LMP) serous (n = 6) and mucinous (n = 11) tumors, serous
carcinomas (n = 16), endometrioid adenocarcinoma (n = 3),
mucinous adenocarcinomas (n = 3), carcinosarcoma (n = 1),
metastatic adenocarcinoma of the breast (n = 1), metastatic
adenocarcinomas of the gastrointestinal tract (n = 5), meta-
static adenocarcinoma of the colon (n = 1), clear cell
carcinoma (n = 1), granulosa cell tumor (n = 4), Leydig cell
tumor (n = 1), and steroid cell tumor (n = 1). The sensitivities
associated with CA125, HE4, ROMA, and RMI for this
cohort of cases were 70.4%, 79.6%, 74.1%, and 63%,
respectively.
When the LMP tumors were classified as low-risk, the
sensitivities for CA125, HE4, ROMA, and RMI increased to
83.8%, 86.5%, 83.8%, and 75.7%, respectively. In addition, the
sensitivities associated with the discrimination between pri-
mary carcinomas of the ovary for CA125, HE4, ROMA, and
RMI were 93.5%, 87.1%, 95.2%, and 87.1%, respectively. Table 2
provides the sensitivity and specificity values established
for CA125, HE4, ROMA, and RMI in both pre-and
post-menopausal women. The optimal cutoff values for these
data were also calculated.
Twelve (92.3%) of the 13 patients diagnosed with
endometrioma had elevated values of CA125, and only
three (23.1%) had increased HE4 values. The ROC curves for
CA125, HE4, ROMA, and RMI were calculated to compare
the accuracy of the four methods. The greatest AUC was
associated with the RMI values (0.861), as compared to the
ROC values for the ROMA (0.824), HE4 (0.777), and CA125
(0.802). The ROC curves were compared using a pairwise
comparison method (10), and no differences were detected
between the four methods. In addition, no differences were
observed in the ROC curves of CA125 and HE4 as compared
to the ROMA and RMI. However, differences were observed
between the HE4 and ROMA values (p= 0.03) in the overall
assessment (Figure 1) and among post-menopausal women
(p= 0.05).
DISCUSSION
Our results indicate that the tumor markers CA125 and
HE4 as well as ROMA and RMI values are useful methods
Table 1 - Characteristics of the studied population.
Age
Menopausal
Status
CA125
(U/ml)
HE4
(pM) RMI
ROMA
(%)
Mean Median
Pre
(N)
Post
(N)
Mean
(SD)
Median
(Range)
Mean
(SD)
Median
(Range)
Mean
(SD)
Median
(Range)
Mean
(SD)
Median
(Range)
Benign 50.7 51 29 37 36.8
(55.5)
17.1
(3 – 293)
76.5
(58,4)
64.8
(12.7 – 325)
72.3
(105.4)
30.3
(0 – 496.8)
15.3
(11)
13.3
(0.8 – 41.5)
LMP* 56.4 58 6 11 147
(266.5)
26.4
(10.5 – 844.5)
101.1
(55.6)
96.1
(24.2 – 193.6)
355.5
(602.2)
168.3
(0 – 2534)
26.4
(17)
24.9
(3 – 67.2)
Malignant 54.7 54 12 25 318.9
(517.8)
138.7
(7.5 – 2856)
263.3
(404.9)
166.6
(2.5 – 2427)
1896.7
(4347)
648
(0 – 25704)
59.1
(30)
61
(0 -99.9)
*LMP: Low Malignant Potential.
Table 2 - The sensitivity and specificity values associated with CA125, HE4, ROMA, and RMI for pre- and post–
menopausal patient groups at the optimal identified cutoff value and the standard cutoff value for each method.
Parameter Optimal cutoff Standard cutoff****
ROC*/
AUC
Cutoff
Value
Sen**
(%) Spe*** (%)
Cutoff
Value
Sen**
(%) Spe*** (%)
All Patients
CA125 0.802 59 U/ml 61.1 86.4 35 U/ml 70.4 74.2
HE4 0.777 87 pM 75.9 77.3 70 pM 79.6 66.7
ROMA 0.824 23.3% 75.9 81.8 ***** 74.1 75.8
RMI 0.861 113.1 77.8 87.9 200 63 92.4
Pre-
menopausal
CA125 0.807 96 U/ml 77.8 82.8 35 U/ml 83.3 55.2
HE4 0.774 68 pM 72.2 82.8 70 pM 72.2 82.8
ROMA 0.791 13.9% 77.8 79.3 13.1% 77.8 69.0
RMI 0.875 244 72.2 96.6 200 72.2 89.7
Post-
menopausal
CA125 0.846 24 U/ml 69.4 86.5 35 U/ml 63.9 89.2
HE4 0.762 104 pM 75.0 78.4 70 pM 83.3 54.1
ROMA 0.840 39.7% 63.9 97.3 27.7% 72.2 81.1
RMI 0.853 113.0 77.8 89.2 200 58.3 94.6
*ROC/AUC=area under the ROC (Receiver Operating Characteristic) curve.
**Sen= Sensitivity.
***Spe= Specificity.
****Standard cutoff: CA125, Bast et al., 198311; HE4, Moore et al., 20086; ROMA, Moore et al. 2010 9; RMI, Jacobs et al., 19908.
*****Cutoff values used for ROMA are different for pre- and post-menopausal women16.
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for differentiating ovarian masses according to whether they
are associated with a high or low risk for developing into
ovarian cancer, and this type of assessment which will
ultimately optimize the referral of patients to reference
centers. We intentionally modified the above methods to
perform an analysis using the available tools in routine
practice. For the ROMA, we used the CA125 kit from
RocheH even though this algorithm had been validated
using the Fujiribios CA125 kit, as we routinely use the
RocheH kit for our services. Although we wanted to ensure
that the current study provided an accurate representation
of the tools available at our hospital, we applied the same
numeric cutoff values proposed by Moore et al. (7).
Moreover, we believe that the small deviations observed
in the analysis presented here did not compromise the
overall findings of the study.
The RMI method originally described by Jacobs et al. (8)
used ultrasound assessment as the sole imaging parameter,
although we included both CT and MRI in our study (as did
Moore et al.) (9). It would be expected that this modification
would improve the results for the RMI than those presented
by Jacobs et al., as CT and MR technologies can more
accurately assess adnexal tumors. However, our study
found that this modification did not provide more accurate
results. In the study by Jacobs et al. (8), the sensitivity and
specificity reached 85.4% and 96.9%, respectively, using a
cutoff value of 200. In the present study, the sensitivity and
specificity values associated with the RMI were 66.7% and
87.9%, respectively, which are lower than those demon-
strated by Jacobs et al. (8). One potential explanation for
these different results may have been the greater hetero-
geneity of histologic types observed in our study. However,
the samples we analyzed demonstrated a profile very
similar to that observed in clinical practice.
To evaluate the accuracy of the four ovarian cancer risk
stratification methods, an AUC was calculated for each
ROC. We calculated ROC values of 80.2% and 77.7% for
CA125 and HE4, respectively, and found no statistical
difference between these values (p= 0.67). In contrast, an
evaluation of the same tumor markers by Moore et al. (9)
found ROC values of 83.6% and 90.8%, respectively, and no
statistically significant differences were observed for these
ROMA and RMI curves either (p= 0.50). However, the study
by Moore et al. (9) reported the AUCs for the ROMA and
RMI to be 91.3% and 84.4%, as compared to the values of
82.4% and 85.5% obtained in our study, respectively. These
differences may also be explained by the more hetero-
geneous quality of the tumors evaluated in our study.
In the current study, the optimal cutoff values associated
with the ROMA were 13.97% and 39.68% for pre- and post-
menopausal women, respectively. The pre-menopausal
ROMA cutoff value in our study was similar that reported
by Moore et al. (9), whereas the post-menopausal value was
higher (13.1% and 27.7%, respectively). The cutoff values
reported by Van Gorp et al. (11) were 16.6% and 35.9% for
pre- and post-menopausal women, respectively, which were
also similar to those identified in our study. The authors of
this previous study also found an overall cutoff value for the
post-menopausal ROMA of 22.2%, which was similar to the
value of 23.3% identified in our study. The use of different
CA125 kits may have resulted in these differences, and the
inclusion of CT and MRI methods may explain the higher
cutoff RMI value obtained in the current study as compared
to the study by Jacobs et al. (8) (275.7 vs. 200, respectively).
One major problem associated with the pre-operative
evaluation of pelvic masses concerns the identification of
LMP tumors and the diagnosis of endometriosis. We found
that the four methods of risk evaluation demonstrated better
performance when LMP tumors were classified as low-risk
tumors. The sensitivity value for CA125 detection was 83.8%
with a specificity of 71.1%, whereas these values were 70.4%
and 74.2%, respectively, when the tumors were classified as
high-risk. In addition, HE4 sensitivity increased from 79.65 to
86.5%, ROMA sensitivity increased from 74.1% to 83.8%, and
RMI sensitivity increased from 63% to 75.7% when these
tumors were classified as low-risk. Although the classification
of LMP tumors remains controversial, clinical and biological
evidence suggests that these tumors can be classified as low-
risk. LMP tumors are associated with a good prognosis, and 5-
year survival rates are approximately 98% for stage I tumors
and 90% for stage III tumors with non-invasive implants (12).
In addition, BRAF and KRAS mutations characterize the low-
grade pathway of ovarian carcinogenesis, and borderline
tumors are identified as precursor lesions of this pathway
(13). Although it is outside the scope of the current study to
discuss the nature and treatment options for LMP tumors,
these types of tumors represent an important differential
diagnosis for pelvic masses. In our cohort, these tumors were
found in 17 (14.2%) cases, which mirrors the frequency of
these tumors observed in common clinical practice. Because
these tumors are low-grade and in most cases do not require
surgical biopsy as a first-line approach, their inclusion in the
low-risk category appears to be acceptable. Therefore, patients
receiving care from non-specialized centers may also be
referred to reference centers for appropriate staging without
compromising their prognosis (12). Moreover, if LMP tumors
are classified as low-risk, the burden related to an influx of
lower-risk patients at specialized centers may be reduced.
The inclusion or exclusion of LMP and other non-
epithelial tumors in the assessment of data is one of the
most important factors affecting the reported accuracy of
these methods. In the study by Moore et al. (6), the
sensitivity of HE4 was found to be 72.9% at a 95%
specificity. In our analysis, only epithelial ovarian cancers
were included, and therefore nine LMP tumors, two non-
epithelial ovarian tumors, and 13 metastatic tumors of the
ovary were excluded. In 2011 from an analysis of patients
with ovarian cancer, Chang et al. (14) evaluated 491 patients
and obtained a sensitivity of 73% and 88% using the
markers HE4 and CA125, respectively. As a result, the
sensitivity value for HE4 was found to be 79.6%, which was
higher than that reported by Moore et al. (6). As previously
Figure 1 - The Receiver Operating Characteristic (ROC) curves for
CA125, HE4, ROMA, and RMI in this patient cohort.
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stated, the sensitivity of HE4 in our study was determined
to be 86.5% with the exclusion of LMP tumors. The
sensitivity and specificity associated with the ROMA values
for the cases analyzed were 74.1% and 75.8%, respectively.
These results were not consistent with those of Moore et al.
(6), which could have been due to the exclusion of non-
epithelial tumors in the previous analysis (7).
Another important differential diagnosis for pelvic
masses is endometriosis, which is the disease that most
often interferes with the accuracy of the methods used for
pre-operative evaluations of cancer risk. In the present
study, 12/13 (92.3%) patients with endometriosis had
CA125 values above 35 U/ml, whereas only 3/13 (23.1%)
patients had HE4 values above 70 pM. The increased
specificity of HE4 for the differentiation between endome-
triosis and ovarian cancer is in agreement with two recently
published studies (15,16), suggesting that the use of both
markers together can improve this type of evaluation.
Despite small variations, the four methods that were
evaluated for their ability to differentiate adnexal masses
(CA125, HE4, ROMA, and RMI) demonstrated similar levels
of accuracy. The RMI was found to have the lowest sensitivity
but provided the best numeric accuracy of the four methods.
The tumor marker HE4 demonstrated the best overall
sensitivity for the evaluation of malignant ovarian tumors
and the differential diagnosis of endometriosis. All of the
parameters demonstrated increased sensitivity when tumors
with low malignancy potential were considered low-risk,
which may be used as an acceptable assessment method for
referring patients to reference centers.
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